
Advent, Sunstone et al. in $60m round for F2G
UK antifungal pharmaceutical company F2G has raised $60m funding in a round led by Sectoral Asset Management.
The round includes capital from new investors Novo, Aisling Capital and Brace Pharma Capital.
Previous investors also took part, including Advent Life Sciences, Novartis Venture Fund, Sunstone Capital and Merifin Capital.
With the new financing, F2G plans to advance its lead compound, F901318 – a clinical-stage candidate for the treatment of invasive aspergillosis and other serious mould infections – and to further develop other earlier-stage assets in its pipeline.
Dr Maha Katabi, private equity partner at Sectoral Asset Management and Dr Martin Edwards, senior partner at Novo, will join the F2G board of directors.
Previous funding
In September 2002, BankInvest Biomedical Ventures led a £4.3m first round of funding for F2G. BankInvest provided £3m of the total from its Biomedical Venture Fund III, Merifin supplied £800,000 and the balance was provided by a small number of private investors.
In August 2003, a second funding round was provided by BankInvest and Merifin; the same investors injected an extra €4.52m in July 2004.
In March 2006, a €7.35m round involved BankInvest again, as well as Astellas Venture Management. In August 2008, BankInvest led an €8.01m round alongside minority investors Astellas and Merifin.
Then, in September 2012, Advent (via its Advent Life Sciences fund), Novartis, Sunstone, Merifin, K Nominees and Astellas invested a combined $30m (€23.91m) in an equity financing round.
Company
F2G is a Manchester-based biotech company focused on the discovery and development of therapies to treat life-threatening invasive fungal infections. It has mainly discovered and developed a new class of antifungal agents called the orotomides.
Established in 1998, F2G was formerly known as Functional Fungal Genomics.
People
Sectoral Asset Management – Dr Maha Katabi (private equity partner).
Novo – Dr Martin Edwards (senior partner).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater